2-DG UPDATE: Dr Reddy's Lab commercially launches 2-deoxy-D-glucose TODAY; Priced it at Rs 990/sachet

Dr Reddy's Laboratories announced the commercial launch of 2-deoxy-D-glucose (2-DG) on Monday. Dr Reddy's will supply to major the government as well as private hospitals across India, the company release said. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India, the release further said. 

2-DG manufactured by Dr Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidised rate offered to government institutions. Enquiries for 2DG can be sent to 2DG@drreddys.com, the company said in its release.

See Zee Business Live TV Streaming Below:

"2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic," Satish Reddy, Chairman at Dr Reddy's said. 
"We are pleased to have worked closely with our long-term industry partner Dr Reddy's Laboratories, Hyderabad, for testing 2-DG as a therapeutic application in the treatment of COVID-19 patients. DRDO has been contributing in the fight against the COVID-19 pandemic with its spin-off technologies" the release said quoting Dr G. Satheesh Reddy, Secretary Department of Defence (R&D) and Chairman at DRDO. 

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's 2-DG is an oral drug. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care. 

Emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021.